Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q3 2026 · 10-Q
Revenue$0.00$0.00— vs Q3 2025 Net Income-$154.17K-$154.17KN/M vs Q3 2025 EPS Diluted$0.00$0.00— vs Q3 2025 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
-$162,763
N/M
Operating Cash Flowderived-$47,667N/M ended May 31, 2026 · filed Jun 24, 2026 · 24 d after period end